Technical Analysis for INKT - MiNK Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.88 | 0.95% | 0.01 |
INKT closed down 4.76 percent on Thursday, April 18, 2024, on 38 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.95% | |
| MACD Bearish Centerline Cross | Bearish | 0.95% | |
| Outside Day | Range Expansion | 0.95% | |
| Wide Bands | Range Expansion | 0.95% | |
| Oversold Stochastic | Weakness | 0.95% | |
| Calm After Storm | Range Contraction | -3.86% | |
| NR7 | Range Contraction | -3.86% | |
| NR7-2 | Range Contraction | -3.86% | |
| Narrow Range Bar | Range Contraction | -3.86% | |
| Wide Bands | Range Expansion | -3.86% |
| Alert | Time |
|---|---|
| Up 3% | about 2 hours ago |
| Up 2% | about 2 hours ago |
| Up 1% | about 2 hours ago |
| Rose Above Previous Day's High | 1 day ago |
| 50 DMA Resistance | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Pharmacy Stem Cell Cell Therapy T Cells Immune Mediated Diseases Natural Killer T Cell Lineage Cell Therapeutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.34 |
| 52 Week Low | 0.75 |
| Average Volume | 111,302 |
| 200-Day Moving Average | 1.19 |
| 50-Day Moving Average | 0.96 |
| 20-Day Moving Average | 1.01 |
| 10-Day Moving Average | 1.05 |
| Average True Range | 0.12 |
| RSI (14) | 43.50 |
| ADX | 26.69 |
| +DI | 31.88 |
| -DI | 19.19 |
| Chandelier Exit (Long, 3 ATRs) | 1.53 |
| Chandelier Exit (Short, 3 ATRs) | 1.15 |
| Upper Bollinger Bands | 1.36 |
| Lower Bollinger Band | 0.65 |
| Percent B (%b) | 0.31 |
| BandWidth | 70.95 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.02 |
| MACD Histogram | -0.029 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.01 | ||||
| Resistance 3 (R3) | 1.02 | 0.99 | 0.98 | ||
| Resistance 2 (R2) | 0.99 | 0.96 | 0.98 | 0.98 | |
| Resistance 1 (R1) | 0.93 | 0.93 | 0.92 | 0.92 | 0.97 |
| Pivot Point | 0.90 | 0.90 | 0.89 | 0.89 | 0.90 |
| Support 1 (S1) | 0.84 | 0.87 | 0.83 | 0.83 | 0.77 |
| Support 2 (S2) | 0.81 | 0.85 | 0.80 | 0.77 | |
| Support 3 (S3) | 0.75 | 0.81 | 0.76 | ||
| Support 4 (S4) | 0.74 |
